China Focus @Europe Vienna | Connect with Chinese Pharma and Investors in Healthcare Innovation

Location: Hilton Vienna Danube Waterfront, Vienna, Austria.

Date: March 27th, 2019

Since the recent reform of China’s drug approval process, clinical trials and new drug approval in China has speeded up. In 2017, 34 pharma products and 5 biotech products were approved, making a record high in the history. It opened the door for drug development companies around the world to the Chinese market and also ignited license-in interest from Chinese public pharma companies.

On March 27th, 2019, "China Focus @ Europe Vienna" organized by MyBioGate was held in Hilton Vienna Danube Waterfront, Vienna, Austria. China Focus @ Europe Vienna forum attracted more than 50 Chinese healthcare leading companies, investors, and Chinese executives. The forum focused on inspiring, educating and engaging cross-border investment and partnership in foremost biopharmaceutical companies and investors globally.  

-                200+ Attendees

-                100+ Chinese Companies and Investors

-                10+ European Countries

-                200+ One-to-one Meetings

-                80% Executive Level Attendees

-                15 Company Presentations 

Echo Hindle-Yang – CEO, MSQ Ventures participated as a special guest moderator at the Panel 4: Partnering Opportunities with Chinese Pharma. Echo held an in-depth debate on the challenging issues with John Xu (Jemincare Therapeutics), Carlos de Sousa (Immunicum AB), Qun Dang (Qilu Pharmaceutical), Mike Robbat (ORIG3N). The discussion was oriented around the future opportunities and challenges of rare diseases and orphan drugs in the China market,

China’s reformation of the registration policy, the differences of healthcare companies and VC institutions regarding the market value assessment. The audience was interactively engaged in the Q&A session with a variety of interesting questions, which reopened debate among panelists.